Motility Disorders and Hirschsprung Disease


Chronic Intestinal Pseudoobstruction

Asim Maqbool
Kristin N. Fiorino
Chris A. Liacouras

Chronic intestinal pseudoobstruction (CIPO) comprises a group of primary and secondary disorders characterized as a motility disorder with the dominant defect of impaired peristalsis; symptoms are consistent with intestinal obstruction in the absence of mechanical obstruction ( Table 358.1 ). The natural history of primary pseudoobstruction is that of a progressive disorder, although there are occasional cases of secondary pseudoobstruction caused by conditions that can transiently or permanently alter bowel motility. The most common cause of acute pseudoobstruction is Ogilvie syndrome (acute pseudoobstruction of the colon). Pseudoobstruction represents a wide spectrum of pathologic disorders from abnormal myoelectric activity to abnormalities of the nerves (intestinal neuropathy) or musculature (intestinal myopathy) of the gut. The organs involved can include the entire gastrointestinal tract or be limited to certain components, although almost always include the small bowel. The distinctive pathologic abnormalities are considered together because of their clinical similarities. For these reasons, CIPO may be thought of more as a clinical syndrome at times.

Table 358.1
Causes of Secondary Chronic Intestinal Pseudoobstruction in Children
From Bitton S, Markowitz JF: Ulcerative colitis in children and adolescents. In Wyllie R, Hyams JS, Kay M, editors: Pediatric gastrointestinal and liver disease, 5th ed, Elsevier, 2016, Philadelphia, Box. 44.3, p. 548.
  • Autoimmune

  • Autoimmune myositis

  • Autoimmune ganglionitis

  • Scleroderma

  • Endocrine

  • Diabetes mellitus

  • Hypoparathyroidism

  • Hypothyroidism

  • Gastrointestinal

    • Celiac disease

    • Eosinophilic gastroenteritis

    • Inflammatory bowel disease

  • Hematology/oncology

    • Multiple myeloma

    • Paraneoplastic syndromes

    • Pheochromocytoma

    • Sickle cell disease

  • Infection

    • Chagas disease

    • Cytomegalovirus

    • Epstein-Barr virus

    • Herpes zoster

    • JC virus

    • Kawasaki disease

    • Postviral neuropathy

  • Medications and toxins

    • Chemotherapy

    • Cyclopentolate and phenylephrine eye drops

    • Diltiazem and nifedipine

    • Fetal alcohol syndrome

    • Jellyfish envenomation

    • Opioid medications

    • Postanesthesia

    • Radiation injury

  • Mitochondrial disorders

    • Mitochondrial neurogastrointestinal encephalomyopathy

  • Musculoskeletal disorders

    • Ehlers-Danlos syndrome

    • Myotonic dystrophy

    • Duchenne muscular dystrophy

  • Rheumatology

    • Amyloidosis

    • Dermatomyositis

    • Polymyositis

    • Systemic lupus erythematous

Most congenital forms of primary pseudoobstruction occur sporadically, although autosomal dominant (SOX10), autosomal recessive (RAD2I, SGOL1, TYMP, POLG), X-linked (FLNA, L1CAM), and familial patterns of inheritance have been identified. Patients with autosomal dominant forms of pseudoobstruction have variable expressions of the disease. Patients with mutations in TYMP and POLG genes present with mitochondrial neurogastrointestinal encephalomyopathy syndrome (MNGIE); MELAS syndrome is another mitochondrial disorder associated with CIPO. MNGIE is characterized by intestinal dysmotility, abdominal pain and distention, emesis, cachexia, ptosis, leukoencephalopathy, peripheral neuropathy (paresthesia, pain), and myopathy. Sixty percent have symptoms (often subtle) before age 20 yr (see Chapter 358.2 ). Acquired pseudoobstruction can follow episodes of acute gastroenteritis, presumably resulting in injury to the myenteric plexus.

In congenital pseudoobstruction, abnormalities of the muscle or nerves can be demonstrated in most cases. In myopathies, the smooth muscle is involved, in which the outer longitudinal muscle layer is replaced by fibrous material. These manifestations of visceral myopathies may be primary or secondary phenomenon. The enteric nervous system is usually altered in neuropathies and may involve disorganized ganglia, hypoganglionosis, or hyperganglionosis. Abnormalities in the interstitial cells of Cajal, the intestinal pacemaker, are classified as mesenchymopathies. In others, mitochondrial defects have been identified.

Clinical Manifestations

More than half the children with congenital pseudoobstruction experience symptoms in the first few mo of life ( Table 358.2 ). Two-thirds of the infants presenting in the first few days of life are born prematurely, and approximately 40% have malrotation of the intestine. In 75% of all affected children, symptoms occur in the first year of life, while the remainder are usually symptomatic within the next several years. Females present with CIPO more than males do during the first year of life, with equal sex distribution in older children. The most common symptoms are abdominal distention (85–95% of patients) and vomiting (55–90%). Constipation, growth failure, and abdominal pain occur in approximately 60% of patients and diarrhea in 25–30%. The symptoms wax and wane in most patients; poor nutrition, psychologic stress, and intercurrent illness tend to exacerbate symptoms. Urinary tract and bladder involvement occurs in 80% of children with myopathic pseudoobstruction and in 20% of those with neuropathic disease. Symptoms can manifest as recurrent urinary tract infection, megacystis, or obstructive symptoms. Megacystis-microcolon–intestinal hypoperistalsis syndrome is a prenatal or neonatal manifestation of CIPO.

Table 358.2
Main Similarities and Differences in Chronic Intestinal Pseudoobstruction in Children, Adolescents, and Young Adults
From Di Nardo G, Di Lorenzo C, Lauro A, et al: Chronic intestinal pseudo-obstruction in children and adults: diagnosis and therapeutic options, Neurogastroenterol Motil 29:e12945, 2017, Table 2.
CHILDREN ADOLESCENTS—YOUNG ADULTS
Etiology Mainly idiopathic Half of cases are secondary to acquired diseases
Histopathology Myopathies and neuropathies Mainly neuropathies
Symptom onset In utero, from birth or early infancy with 65–80% of patients symptomatic by 12 mo of age Median age of onset at 17 yr
Clinical features Occlusive symptoms at birth and/or chronic symptoms without free intervals
Urologic involvement is commonly encountered ranging from 36% to 100% pediatric case series
High risk of colonic and small bowel volvulus secondary to severe gut dilation, dysmotility, congenital bridles, or concurrent malrotation
Chronic abdominal pain and distension with superimposed acute episodes of pseudoobstruction
Urinary bladder involvement not so often reported
Natural history Myopathic CIPO, urinary involvement and concurrent intestinal malrotation are poor prognostic factors The ability to restore oral feeding and the presence of symptoms <20 yr of age is associated with a low mortality; while, systemic sclerosis and severe/diffuse esophageal and intestinal dysmotility are associated with a high mortality
Diagnostic approach Specialized tests (e.g., intestinal manometry) often difficult to perform; noninvasive, radiation-free imaging tests are warranted Various methodologic approaches usually starting from endoscopy and radiological tests up to more sophisticated functional exams
Nutritional therapy To ensure normal growth extensively hydrolyzed and elemental formulas are often empirically used to facilitate intestinal absorption To improve nutritional status and prevent malnutrition
Pharmacologic therapy Small number/sample size-controlled trials Small number/sample-size controlled trials; few conclusions can be drawn for most drugs
Surgical therapy Venting ostomies (although characterized by high complication rates) possibly helpful; surgery as a “bridge” to transplantation may be indicated in highly selected cases Venting ostomies can be helpful; resective surgery may be indicated in accurately selected patients (i.e., cases with proven segmental gut dysfunction)

Diagnosis

The diagnosis of pseudoobstruction is based on the presence of compatible symptoms in the absence of mechanical obstruction ( Fig. 358.1 ). Plain abdominal radiographs demonstrate air-fluid levels in the intestine. Neonates with evidence of obstruction at birth may have a microcolon. Contrast studies demonstrate slow passage of barium; water-soluble agents should be considered. Esophageal motility is abnormal in about half the patients. Antroduodenal (small intestinal) motility and gastric emptying studies have abnormal results if the upper gut is involved ( Table 358.3 ). The clinical manifestations depend in large part to the areas of the gastrointestinal tract that are involved, with milder forms more common in older children. Although counterintuitive, older children with CIPO may present with both abdominal distention and diarrhea, related to small bowel bacterial overgrowth because of altered motility. Other presentations may include constipation and bilious emesis, as well as failure to thrive, as a consequence of decreased enteral feeding tolerance.

Fig. 358.1, Synoptic view of the chronic intestinal pseudoobstruction (CIPO) spectrum.

Table 358.3
Findings in Pseudoobstruction
From Steffen R: Gastrointestinal motility. In Wyllie R, Hyams JS, Kay M, editors: Pediatric gastrointestinal and liver disease, ed 3, Philadelphia, 2006, WB Saunders, p. 66.
GI SEGMENT FINDINGS *
Esophageal motility Abnormalities in approximately half of CIPO, although in some series up to 85% demonstrate abnormalities
Decreased LES pressure
Failure of LES relaxation
Esophageal body: low-amplitude waves, poor propagation, tertiary waves, retrograde peristalsis, occasionally aperistalsis
Gastric emptying May be delayed
EGG Tachygastria or bradygastria may be seen
ADM Postprandial antral hypomotility is seen and correlates with delayed gastric emptying
Myopathic subtype: low-amplitude contractions, <10-20 mm Hg
Neuropathic subtype: contractions are uncoordinated, disorganized
Absence of fed response
Fasting MMC is absent, or MMC is abnormally propagated
Colonic Absence of gastrocolic reflex because there is no increased motility in response to a meal
ARM Normal rectoanal inhibitory reflex
ADM, antroduodenal manometry; ARM, anorectal manometry; CIPO, chronic intestinal pseudoobstruction; EGG, electrogastrography; GI, gastrointestinal; LES, lower esophageal sphincter; MMC, migrating motor complex.

* Findings can vary according to the segment(s) of the GI tract that are involved.

The initial focus is to rule out anatomic obstruction and to assess for bladder involvement, because that is a frequent and significant extraintestinal manifestation of concern. Manometric evidence of a normal migrating motor complex and postprandial activity should redirect the diagnostic evaluation. CIPO due to an intestinal myopathy may demonstrate manometry evidence of low-amplitude contractions, whereas CIPO due to enteric neuropathy demonstrates normal amplitude but poorly organized contractions (nonperistaltic or tonic). Anorectal motility is normal and differentiates pseudoobstruction from Hirschsprung disease. Full-thickness intestinal biopsy might show involvement of the muscle layers or abnormalities of the intrinsic intestinal nervous system.

The differential diagnosis is broad and includes such etiologies as Hirschsprung disease, mitochondrial neurogastrointestinal encephalomyopathy, mechanical obstruction, psychogenic constipation, neurogenic bladder, and superior mesenteric artery syndrome. Secondary causes of ileus or pseudoobstruction that should be considered include medication side effects, infectious etiologies, metabolic disturbances, immunologic disorders, oncologic processes, vasculitides, neuropathies, and myopathies (see Table 358.1 ). Examples include use of opiates hypokalemia, hypothyroidism, hypokalemia, diabetic neuropathy, porphyria, amyloidosis, Chagas disease, scleroderma, hereditary angioedema, mitochondrial disorders, and radiation, and these must be excluded. Other causes of abdominal distention such as small bowel bacterial overgrowth and aerophagia may present similarly and should be considered. Small bowel bacterial overgrowth is a complication of CIPO.

Treatment

Nutritional support is the mainstay of treatment for pseudoobstruction. Thirty to 50% of patients require partial or complete parenteral nutrition. Some patients can be treated with intermittent enteral supplementation, whereas others can maintain themselves on selective oral diets. Prokinetic drugs are generally used, although studies have not shown definitive evidence of their efficacy. Isolated gastroparesis can follow episodes of viral gastroenteritis and spontaneously resolves, usually in 6-24 mo. Erythromycin, a motilin receptor agonist, and cisapride, a serotonin 5-HT 4 receptor agonist, may enhance gastric emptying and proximal small bowel motility and may be useful in this select group of patients. Metoclopramide, a prokinetic and antinausea agent, is effective in gastroparesis, although side effects, such as tardive dyskinesia, limit its use. Domperidone, an antidopaminergic agent, is a prokinetic agent that can be considered. Pain management is difficult and requires a multidisciplinary approach.

Symptomatic small bowel bacterial overgrowth is usually treated with rotated nonabsorbable oral antibiotics and/or probiotics. Bacterial overgrowth can be associated with steatorrhea and malabsorption. Octreotide, a long-acting somatostatin analog, has been used in low doses to treat small bowel bacterial overgrowth. Patients with acid peptic symptoms are generally treated with acid suppression. Many patients with CIPO benefit from a gastrostomy, and some benefit from decompressive enterostomies ( Fig. 358.2 ). Colectomy with ileorectal anastomosis is beneficial if the large bowel is the primary site of the motility abnormality. Bowel transplantation may benefit selected patients with CIPO. The prognosis is better for patients without urinary tract involvement and for those with neuropathic etiologies over myopathic disorders.

Fig. 358.2, Photograph of a child with chronic intestinal pseudoobstruction who improved clinically after ileostomy creation. He receives enteral feeding through his jejunal feeding tube, whereas his gastrostomy tube remains to straight drain.

Bibliography

  • Chumpitazi B, Nurko S: Pediatric gastrointestinal motility disorders: challenges and a clinical update. Nat Rev Gastroenterol Hepatol 2008; 4: pp. 140-148.
  • Cucchiara S, Borrelli O, Salvia G, et. al.: A normal gastrointestinal motility excludes chronic intestinal pseudo-obstruction in children. Dig Dis Sci 2000; 45: pp. 258-264.
  • Di Nardo G, Blandizzi C, Volta U, et. al.: Review article: molecular, pathological and therapeutic features of human enteric neuropathies. Aliment Pharmacol Ther 2008; 28: pp. 25-42.
  • Di Nardo G, Di Lorenzo C, Lauro A, et. al.: Chronic intestinal pseudo-obstruction in children and adults: diagnosis and therapeutic options. Neurogastroenterol Motil 2017; 29: pp. e12945.
  • Faure C: Chronic intestinal Pseudo-obstruction syndrome.Walker WAGoulet OPediatric gastrointestinal disease. Pathohysiology, Diagnosis, Management.2004.
  • Gabbard S, Lacy B: Chronic intestinal pseudo-obstruction. Nutr Clin Pract 2013; 28: pp. 307-316.
  • Haas S, Bindl L, Fischer HP: Autoimmune enteric leiomyositis: a rare cause of chronic intestinal pseudo-obstruction with specific morphological features. Human Path 2005; 36: pp. 576-580.
  • Kleinman R et. al.Chronic intestinal pseudo-obstruction.2004.BC DeckerHamilton, Ontario:pp. 1044-1054.
  • Knowles CH, Lindberg G, Panza E, De Giorgio R: New perspectives in the diagnosis and management of enteric neuropathies. Nat Rev Gastroenterol Hepatol 2013; 10: pp. 206-218.
  • Lapointe SP, Rivet C, Goulet O, et. al.: Urological manifestations associated with chronic intestinal pseudo-obstructions in children. J Urol 2002; 168: pp. 1768-1770.
  • Mousa H, Hyman PE, Cocjin J, et. al.: Long-term outcome of congenital intestinal pseudo-obstruction. Dig Dis Sci 2002; 47: pp. 2298-2305.
  • Nurko S: Motility disorders in children. Pediatr Clin N Am 2017; 64: pp. 593-612.
  • Rahman S: Gastrointestinal and hepatic manifestations of mitochondrial disorders. J Inherit Metab Dis 2013; 36: pp. 659-673.
  • Venkatasubramani N, Sood M: Motility disorders of the gastrointestinal tract. Indian J Pediatr 2006; 73: pp. 927-930.

Mitochondrial Neurogastrointestinal Encephalomyopathy

Asim Maqbool
Chris A. Liacouras

Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is a multisystem autosomal recessive disease that initially presents with severe gastrointestinal disturbances; the neurologic manifestations usually occur later in the illness and may initially be subtle or asymptomatic.

MNGIE is caused by a mutation in the nuclear DNA TYMP gene encoding thymidine phosphorylase that results in abnormalities in intergenomic communication with resulting instability of mitochondrial DNA (some patients have mutations on POLG1 ). There are at least 50 individual mutations with a poor genotype-phenotype correlation and varying manifestations within each family. Consanguinity is present in 30% of families.

MNGIE affects both males and females and is usually diagnosed in the 2nd and 3rd decade (average age: 18 yr; range: 5 mo-35 yr). Onset is usually around age 12 yr, but there is often a 5- to 10-yr delay in the diagnosis.

MNGIE initially presents with gastrointestinal symptoms. Severe intestinal dysmotility and gastroparesis are associated with early satiety, postprandial emesis, episodic pseudoobstruction, diarrhea, constipation, and abdominal pain and cramping, which leads to significant cachexia. Because of the age of onset, emesis, early satiety, and cachexia patients are often misdiagnosed with an eating disorder.

Most often, following the onset of gastrointestinal manifestations, ptosis, progressive external ophthalmoplegia, hearing loss, myopathy, and peripheral neuropathy may develop. The neuropathy is either demyelinating or a mixed axonal demyelinating type and manifests as weakness, decreased or absent deep tendon reflexes, and paresthesias. Leukoencephalopathy is initially asymptomatic and noted on MRI as patchy lesions predominantly in the cortex but also in the basal ganglia and brainstem. Eventually the central nervous system lesions become diffuse and confluent. A small number of patients develop cognitive impairment or dementia.

The diagnosis is suggested by the constellation of gastrointestinal and neurologic symptoms, lactic acidosis, ragged red fibers, and cytochrome C oxidase–deficient fibers seen in most patients on muscle biopsy. Reduced activity of thymidine phosphorylase enzyme and elevated plasma levels of thymidine and deoxyuridine are often diagnostic; genetic testing for the mutation or other genes (POLG1) is recommended.

Treatment is focused on providing sufficient nutritional support and avoidance of infectious complications and of nutritional deficiencies. Domperidone has been used for nausea and emesis, antibiotics for small bowel bacterial overgrowth, amitriptyline or gabapentin for neuropathic pain, and parenteral alimentation for nutritional support. Opiates and any medications that affect intestinal motility or mitochondrial function must be avoided. Stem cell transplantation has been successful in a small number of patients.

Overall the prognosis is poor, with few surviving into the 4th or 5th decade.

Bibliography

  • Bariş Z, Eminoğlu T, Dalgiç B, et. al.: Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): case report with a new mutation. Eur J Pediatr 2010; 169: pp. 1375-1378.
  • D'Angelo R, Rinaldi R, Carelli V, et. al.: ITA-MNGIE: an Italian regional and national survey for mitochondrial neuro-gastro-intestinal encephalomyopathy. Neurol Sci 2016; 37: pp. 1149-1151.
  • Garone C, Tadesse S, Hirano M: Clinical and genetic spectrum of mitochondrial neurogastrointestinal encephalomyopathy. Brain 2011; 134: pp. 3326-3332.
  • Hirano M: Mitochondrial neurogastrointestinal encephalopathy disease.Adam MPArdinger HHPagon RA et. al.GeneReviews® [internet].2005.University of Washington, SeattleSeattle (WA):pp. 1993-2018. Available from https://www.ncbi.nlm.nih.gov/books/NBK1179/ Apr 22; [Updated 2016 Jan 14]
  • Sivadasan A, Muthusamy K, Kumar A, et. al.: Pearls and Oy-sters: mitochondrial neurogastrointestinal encephalomyopathy. Neurology 2016; 86: pp. e147-e150.
  • Tang S, Dimberg EL, Milone M, Wong LJC: Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)-like phenotype: an expanded clinical spectrum of POLG1 mutations. J Neurol 2012; 259: pp. 862-868.

You're Reading a Preview

Become a Clinical Tree membership for Full access and enjoy Unlimited articles

Become membership

If you are a member. Log in here